UNBS5162 has shown potential in various cancer research studies due to its ability to inhibit tumor growth and induce apoptosis in cancer cells. It has been particularly studied for its effects on prostate cancer, where it demonstrated the ability to reduce tumor size and improve survival rates in preclinical models. Additionally, it has been explored for its anti-angiogenic properties, which help in cutting off the blood supply to tumors, thereby limiting their growth. Researchers are also investigating its role in overcoming drug resistance in certain cancers, making it a promising candidate for combination therapies. Its application extends to other cancer types, including breast and colon cancers, where it has shown efficacy in reducing cell proliferation and metastasis. Further studies are ongoing to explore its full therapeutic potential and safety profile in clinical settings.